Skip Navigation LinksHome > March 2009 - Volume 28 - Issue 3 > Early Initiation of Lopinavir/Ritonavir in Infants Less Than...
Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0b013e31818cc053
Original Studies

Early Initiation of Lopinavir/Ritonavir in Infants Less Than 6 Weeks of Age: Pharmacokinetics and 24-Week Safety and Efficacy

Chadwick, Ellen Gould MD*; Pinto, Jorge MD, DSc†; Yogev, Ram MD*; Alvero, Carmelita G. MS‡; Hughes, Michael D. PhD‡; Palumbo, Paul MD§; Robbins, Brian PhD¶; Hazra, Rohan MD∥; Serchuck, Leslie MD∥; Heckman, Barbara E. BS**; Purdue, Lynette PharmD††; Browning, Renee RN, MSN††; Luzuriaga, Katherine MD‡‡; Rodman, John PharmD¶#; Capparelli, Edmund PharmD§§; the International Maternal Pediatric Adolescent Clinical Trials Group (IMPAACT) P1030 Team

Collapse Box

Abstract

Background: With increasing recognition of the benefits of early antiretroviral therapy initiation in perinatally HIV-infected infants, data are needed regarding the pharmacokinetics (PK), safety, and efficacy of recommended first-line protease inhibitors such as lopinavir/ritonavir (LPV/r).

Methods: A prospective, phase I/II, open-label, dose-finding trial evaluated LPV/r at a dose of 300/75 mg/m2 twice daily plus 2 nucleoside analogs in HIV-1-infected infants ≥14 days to <6 weeks of age. Intensive 12-hour PK evaluations were performed after 2 weeks of LPV/r therapy, and doses were modified to maintain LPV predose concentrations >1 μg/mL and area under the curve (AUC) <170 μg hr/mL.

Results: Ten infants enrolled [median age 5.7 (range, 3.6–5.9) weeks] with median HIV-1 RNA of 6.0 (range, 4.7–7.2) log10 copies/mL; all completed 24 weeks of follow-up. Nine completed the intensive PK evaluation at a median LPV dose of 267 (range, 246–305) mg/m2 q12 hours; median measures were AUC = 36.6 (range, 27.9–62.6) μg hr/mL; predose concentration = 2.2 (range, 0.99–4.9) μg/mL; maximum concentration = 4.76 (range, 2.84–7.28) μg/mL and apparent clearance (L/h/m2) = 6.75 (range, 2.79–12.83). Adverse events were limited to transient grade 3 neutropenia in 3 subjects. By week 24, 2 of 10 subjects had experienced a protocol-defined virologic failure.

Conclusions: Although the LPV AUC in this population was significantly lower than that observed in infants ages 6 weeks to 6 months, LPV/r-based antiretroviral therapy in doses of 300/75 mg/m2 BID was well tolerated and resulted in virologic control in 8 of 10 infants by 24 weeks. Additional investigation is needed to understand the long-term implications of the lower LPV exposure in this age group.

© 2009 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.